Medical Countermeasures Phase 1 Trial Begins for Oxford University’s ChAdOx1 Plague Vaccine by Global Biodefense Staff July 26, 2021
Funding News NIAID to Create New Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern by Global Biodefense Staff July 13, 2021
Medical Countermeasures COVID-19 Vaccine Boosters: Is a Third Dose Really Needed? by Global Biodefense Staff July 9, 2021
Medical Countermeasures What is Thrombocytopenia, the Rare Condition Possibly Linked to the AstraZeneca Vaccine? by Global Biodefense Staff April 8, 2021
Medical Countermeasures National Vaccine Trial Will Focus on Those with History of Severe Allergies or Mast Cell Disorder by Global Biodefense Staff April 7, 2021
Medical Countermeasures New Insights on Cause of Rare Anaphylaxis Following COVID-19 Vaccination by Global Biodefense Staff April 7, 2021
Medical Countermeasures How Good Is the AstraZeneca Vaccine – And Is It Really Safe? by Global Biodefense Staff March 23, 2021
Medical Countermeasures How Effective is the First Shot of the Pfizer or Moderna Vaccine? by Global Biodefense Staff March 20, 2021
Medical Countermeasures Applying Lessons from Annual Flu Vaccine Strain Selection to COVID Variants by Global Biodefense Staff March 19, 2021
Medical Countermeasures mRNA Treatment Shows Promise for Stopping Flu and COVID-19 Viruses by Global Biodefense Staff March 19, 2021
Medical Countermeasures Why We’ll Get COVID Booster Vaccines Quickly and How We Know They’re Safe by Global Biodefense Staff March 19, 2021
Industry News OSU’s New Vaccine Candidate for COVID-19 Capitalizes on Measles Vaccine’s Successful History by Global Biodefense Staff March 16, 2021
Medical Countermeasures New Evidence COVID-19 Antibodies, Vaccines Less Effective Against Worrisome Variants by Global Biodefense Staff March 15, 2021
Medical Countermeasures AstraZeneca Vaccine: Careless Talk Has Dented Confidence and Uptake in Europe by Global Biodefense Staff March 11, 2021
Medical Countermeasures WRAIR, Duke Scientists Find Evidence of Monoclonal Antibody Activity Against Malaria by Global Biodefense Staff March 5, 2021
Industry News DARPA Awards Nucleic Acids On-Demand (NOW) Contract to GE Research and Collaborators by Global Biodefense Staff March 2, 2021
Medical Countermeasures How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines? by Global Biodefense Staff March 2, 2021
Medical Countermeasures Key Questions About South Africa’s Vaccine Rollout Plan by Global Biodefense Staff March 2, 2021
Medical Countermeasures Watch: BARDA Director Talks About Emergency Use Authorization of Third COVID-19 Vaccine by Global Biodefense Staff March 1, 2021
Infectious Diseases How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects? by Global Biodefense Staff February 23, 2021
